The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Evaluating teclistamab step-up dosing & dose de-escalation in R/R myeloma in the real-world setting
Rahul Banerjee, MD, FACP, Fred Hutchinson Cancer Center, Seattle, WA, discusses the findings of a retrospective analysis that investigated teclistamab step-up dosing and treatment dose schedule de-escalation in the real-world setting. Dr Banerjee highlights that dosing patterns are evolving with the reduction of time toxicity in mind, as reflected by the fact that 20-30% of patients included in the analysis were de-escalated, some as soon as three months into treatment. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Adaptive Biotechnologies, Bristol-Myers Squibb/Celgene, Caribou Biosciences, Genentech, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Legend Biotech, Pfizer, Sanofi, SparkCures; Research Funding: Abbvie, Bristol-Myers Squibb/Celgene, Janssen, Novartis, Pack Health/Quest Diagnostics, Prothena, Sanofi.
